The HF-AF ENERGY Trial: Attenuate atrial fibrillation with nicotinamide riboside (niagen)

The HF-AF ENERGY Trial: Attenuate atrial fibrillation with nicotinamide riboside (niagen) - The HF-AF ENERGY Trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON52394

Enrollment

Registered

2022-04-08

Start date

2022-05-13

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Patients will be taking the commercially available dietary supplement nicotinamide riboside (Tru Niagen® ChromaDex®), a form of vitamin B3. In earlier studies, this compound was shown to enhance NAD

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Patients diagnosed with paroxysmal or persistent AF • Left ventricle function

Exclusion criteria

Exclusion criteria: • Permanent AF • Hemodynamic instability • Absence of atrial sensing • Malabsorption diseases • Metabolic diseases • Inflammatory disease

Design outcomes

Primary

Measure	Time frame
Our primary objective is to investigate whether niagen normalizes blood-based energy metabolites, mitochondrial levels, and proteostasis levels.	—

Secondary

Measure	Time frame
To examine whether niagen reduces AF burden in patients with ischemic and/or non-ischemic heart disease.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)